Page 14 - Bharat Biotech

Brazil: Covaxin manufacturing facility fails to meet CGMP standards

Covaxin has demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials

Supply chain threats

Vaccine nationalism shows how the pandemic has stressed trade

Bharat Biotech, CSIR collaborate to make raw material for vaccines

India now imports adjuvants and other chemicals for vaccine manufacturing

At $2.06 per dose, India pays the least for AstraZeneca Covid-19 vaccine

The price paid by different governments for a vaccine dose - including for the same vaccine - varies across countries, Unicef data shows

SII, Bharat Bio seek central fund injection to ramp up vaccine production

SII, Bharat Biotech want to increase production to meet domestic, foreign demand

Covaxin manufacturing may get a booster shot as demand for vaccines grows

Bharat Biotech also has another site at Bengaluru that is currently making vaccines other than Covaxin

Supply slipping, Centre to speed up Covid-19 vaccine delivery to states

Vaccine makers asked to send more doses to central government on priority

One year on

Ravages of last year's lockdown may still affect economy

Nepal gives emergency use approval to Bharat Biotech's Covid-19 vaccine

Nepal's national drug regulatory authority granted emergency use approval to Bharat Biotech's Covaxin, becoming the third country to approve India's indigenously developed Covid-19 vaccine

Vaccinating India: What next?

We must pull out all the stops to win the race against the virus. And trust each other to do the right thing

Clinically tried and tested: Bharat Biotech boss Ella wins Covaxin fight

Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January

Bharat Biotech's Covaxin gets authorisation for emergency use: V K Paul

So far 1.9 million people in the country have been given Covaxin, of whom 311 showed some side effects

Top headlines: Bharat Biotech's Covaxin off trial, IDBI Bank out of PCA

Saudi Aramco's $44-billion refinery project at Nanar in Ratnagiri has become a bone of contention between the Maharashtra government and the Centre

Covid-19 vaccine: Bharat Biotech's Covaxin goes off clinical trial mode

Expert panel recommends emergency use authorisation

Bharat Biotech's Covaxin safe, immunises for at least 3 months: Lancet

Probability of side effects from vaccine 10-12%, 6x lower than other shots

India's massive Covid vaccine campaign boosted by PM Modi receiving shot

Almost 21 million shots have been administered in India so far, up from 5.4 million a month ago

10 mn doses from India won't impact poor nations' vaccine access, says UK

UK Vaccine Deployment Minister Nadhim Zahawi has defended a shipment of 10 million doses of Covishield en route from India amid some concerns that it would impact supplies of poorer nations

India Coronavirus Dispatch: New computational tool to track Covid mutations

Parents more ready to send kids to school, trial candidates wonder if they got vaccine or placebo, Antibodies appear faster if exposed to virus earlier-news relevant to India's fight against Covid-19

Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection

Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot

Covaxin shows 81% efficacy in phase-3 trials, says Bharat Biotech

Firm is gearing up to produce 40 million doses a month. Two Bio-safety Level-3 facilities (which can deal with deadly and contagious viruses) have been set up, third is on the way